{"ModuleTitle": "Company Description", "CompanyName": "Omeros Corporation", "Symbol": "OMER", "Address": "201 ELLIOTT AVENUE WEST, SEATTLE, Washington, 98119, United States of America", "Phone": "206-676-5000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a commercial-stage biopharmaceutical company committed to discovering,\r\ndeveloping and commercializing small-molecule and protein therapeutics for\r\nlarge-market as well as orphan indications targeting inflammation,\r\ncomplement-mediated diseases, disorders of the central nervous system and\r\nimmune-related diseases, including cancers.\r\n\r\nOur drug product OMIDRIA\u00ae is marketed in the United States for use during\r\ncataract surgery or intraocular lens (\"IOL\") replacement for adult and pediatric\r\npatients. We have multiple Phase 3 and Phase 2 clinical-stage development\r\nprograms in our pipeline, which are focused on: complement-mediated disorders,\r\nincluding HSCT-TMA, IgA nephropathy and aHUS, as well as addiction. In addition,\r\nwe have a diverse group of preclinical programs, including GPR174, a novel\r\ntarget in immuno-oncology that modulates a new cancer immunity axis that we\r\nrecently discovered.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f02%2f0001558370-20-001891.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "George A. Gaitanaris", "title": "Chief Scientific Officer & Vice President-Science"}, {"name": "Gregory A. Demopulos", "title": "Chairman, President & Chief Executive Officer"}, {"name": "J. Steven Whitaker", "title": "Chief Medical Officer"}, {"name": "Michael A. Jacobsen", "title": "Chief Financial Officer, Treasurer & VP"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}